000 04061nam a22005175i 4500
001 vtls000542905
003 RU-ToGU
005 20210922082417.0
007 cr nn 008mamaa
008 160915s2014 gw | s |||| 0|eng d
020 _a9783319051048
_9978-3-319-05104-8
024 7 _a10.1007/978-3-319-05104-8
_2doi
035 _ato000542905
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aCancer Immunotherapy Meets Oncology
_helectronic resource
_bIn Honor of Christoph Huber /
_cedited by Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee.
260 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2014.
300 _aXX, 246 p. 19 illus., 18 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aImmunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients -- How T cells single out tumor cells: 'and that has made all the difference' -- Tregs and Immune Inhibition -- Regulatory Landscape for Cancer Immunotherapy -- Immunoguiding -- Onco-Immunology Framework and Immunomodulatory Antibodies -- Immunotherapies: Peptide-based Vaccines and HPV Malignancies.- Dendritic cell based cancer vaccines.- RNA Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.- Engineered Antibodies to Engage Immune Cells to the Tumor -- TCRs and TCR Therapy -- CAR Therapy.- Cancer Entities: Melanoma -- Prostate Cancer/Sipuleucel and RNA Vaccines -- Recent advances in the immunotherapy of renal cell cancer and other solid tumors -- Gastric Cancer -- NSCLC -- Breaking tolerance by allogeneic lymphocyte therapy.- Biomarkers: Exploring Immunogenic Cell Death for Patient Benefit -- Circulating Tumor Cells -- Genomics Meets Oncology -- Featured Chapters: Oncolytic Viruses -- Pharma View on Immunotherapy -- Final Remarks.
520 _aThis book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.   Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
650 0 _amedicine.
_9566220
650 0 _aOncology.
_9303086
650 0 _aImmunology.
_9303380
650 0 _aToxicology.
_9302218
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aOncology.
_9303086
650 2 4 _aCancer Research.
_9566267
650 2 4 _aPharmacology/Toxicology.
_9302222
650 2 4 _aImmunology.
_9303380
700 1 _aBritten, Cedrik Michael.
_eeditor.
_9448668
700 1 _aKreiter, Sebastian.
_eeditor.
_9448669
700 1 _aDiken, Mustafa.
_eeditor.
_9448670
700 1 _aRammensee, Hans-Georg.
_eeditor.
_9448671
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-05104-8
912 _aZDB-2-SME
999 _c400277